RWJ-270201 BioCryst Pharmaceuticals/Johnson & Johnson

Document Type

Article

Journal/Book Title/Conference

RWJ-270201 BioCryst Pharmaceuticals/Johnson & Johnson

Volume

1

Publication Date

2000

First Page

421

Last Page

424

Abstract

RWJ-270201, the lead compound in a series of influenza neuraminidase inhibitors, is under development by BioCryst for the potential treatment of influenza [214908], [337716]. Phase III trials commenced in North America and Europe in February 2000 [355053]. Phase II studies were performed to test the effectiveness of RWJ-270201 at reducing viral titers in infected patients. Data showed that the compound was well tolerated and produced statistically significant reductions in viral titers [337716]. Under a worldwide influenza collaboration formed in September 1998, two subsidiaries of Johnson & Johnson, the RW Johnson Pharmaceutical Research Institute and Ortho McNeil, have received exclusive worldwide rights to RWJ-270201 [298487].

Comments

Current Opinion in Investigational Drugs 1:421-424. PMID: 11249693

This document is currently not available here.

Share

COinS